Prospective Study Demonstrates Accuracy and Potential

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Prospective Study Demonstrates Accuracy and Potential Clinical Impact of Nanosphere's Verigene Gram-Positive Blood Culture Test

NORTHBROOK, IL--(Marketwired - Jul 2, 2013) - Nanosphere, Inc. ( NASDAQ : NSPH ), a leader in the development and commercialization of advanced molecular diagnostics systems, today announced publication of a prospective, multicenter study that illustrates the high diagnostic accuracy and potential clinical impact of the company's FDA-cleared Verigene® Gram-Positive Blood Culture (BC-GP) Test in the peer-reviewed, open-access journal PLOS Medicine , published by the Public Library of Science.

The results reported in this manuscript, authored by leading experts in microbiology and molecular diagnostics, demonstrate the performance of the Verigene BC-GP Test in simultaneously detecting and identifying Staphylococcus aureus and 11 other gram-positive bacterial gene targets known to cause bloodstream infections and three genetic resistance determinants (the mec A, van A, and van B genes), directly from positive blood culture media. In addition, a retrospective analysis of turn-around time found that the Verigene BC-GP Test identified methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) species -- two especially deadly causes of bloodstream infection -- an average of 42 hours faster than reference methods.

"The study concluded that the Verigene BC-GP Test is capable of detecting the leading causes of gram-positive bacterial bloodstream infections as well as genetic markers for methicillin resistance in Staphylococcus aureus and vancomycin resistant Enterococcus directly from positive blood cultures, and has the potential to markedly reduce turn-around time for reporting," said Dr. Nathan A. Ledeboer, Associate Professor of Pathology at the Medical College of Wisconsin.

"We are very pleased these study results have been published in PLOS Medicine , an evidence-based journal that focuses on diseases that cause the greatest healthcare and economic burden worldwide," said Michael McGarrity, Nanosphere's president and chief executive officer. "These results are significant as they further validate the compelling value of the Verigene BC-GP Test in enabling rapid analysis and reporting of this time-critical, clinically actionable information to physicians. Our tests have been designed based on comprehensive market feedback to work hand-in-hand with laboratory best practices to provide physicians with the optimal set of results for clinical decision making. Furthermore, we believe the Verigene System's ability to directly detect a comprehensive panel of bacterial DNA targets without the use of PCR is ideally and uniquely suited to the challenge of accurately identifying organisms in blood culture media."

The manuscript, published under the title "Multiplex Identification of Gram-positive Bacteria and Resistance Determinants Directly from Positive Blood Culture Broths: Evaluation of an Automated Microarray-Based Nucleic Acid Test," was composed by Blake W. Buchan 1 , Christine C. Ginocchio 2,3 , Ryhana Manji 2 , Robert Cavagnolo 4 , Preeti Pancholi 5 , Lettie Swyers 5 , Richard B. Thomson Jr. 6 , Christopher Anderson 6 , Karen Kaul 6 , and Nathan A. Ledeboer 1 .

With an impact factor of 16, PLOS Medicine is the leading open-access medical journal, providing an influential venue for outstanding research and commentary on the major challenges to human health worldwide.

About Verigene® Gram-Positive Blood Culture Nucleic Acid Test

The Verigene® Gram-Positive Blood Culture Nucleic Acid (BC-GP) Test performed using the sample-to-result Verigene System is a qualitative, multiplexed in vitro diagnostic test for the simultaneous detection and identification of potentially pathogenic gram-positive bacteria which may cause bloodstream infection. These include the following organisms and antibiotic resistance markers:

Staphylococcus spp. Streptococcus spp. Listeria spp. Enterococcus faecalis Enterococcus faecium Staphylococcus aureus Staphylococcus epidermidis Staphylococcus lugdunensis Streptococcus pneumoniae Streptococcus anginosus group Streptococcus agalactiae Streptococcus pyogenes

And

mecA gene, conferring methicillin resistance vanA and vanB genes, conferring vancomycin resistance

The Verigene BC-GP Test is performed directly on blood culture bottles identified as positive by a continuous monitoring blood culture system and which contain gram-positive bacteria. The Verigene BC-GP Test is indicated for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of bacterial bloodstream infections; however, it is not to be used to monitor these infections. Sub-culturing of positive blood cultures is necessary to recover organisms for susceptibility testing, identify organisms not detected by the Verigene BC-GP Test, differentiate mixed growth, associate antimicrobial resistance marker genes to a specific organism, or for epidemiological typing.

About Nanosphere, Inc.

Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene® System, for multiplexed infectious disease, genetic, and ultra-sensitive protein testing. This easy-to-use platform offers laboratories a convenient, simple, and cost-effective solution for highly sensitive nucleic acid and protein testing. Nanosphere is based in Northbrook, IL.

For additional information regarding Nanosphere's infectious disease products, please contact Nanosphere at IDtesting@nanosphere.us or visit www.nanosphere.us .

Affiliations

1 Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America,

2 North Shore-LIJ Health System, New York, New York, United States of America,

3 Hofstra North Shore-LIJ School of Medicine, Hempstead, New York, United States of America,

4 med fusion LLC, Lewisville, Texas, United States of America,

5 Department of Pathology, The Ohio State University Medical Center, Columbus, Ohio, United States of America,

6 Department of Pathology; NorthShore University HealthSystem, Evanston, Illinois, United States of America

Except for historical information, the matters discussed in this press release are "forward-looking statements" and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Nanosphere's ability to develop commercially viable products; (ii) Nanosphere's ability to achieve profitability; (iii) Nanosphere's ability to produce and market its products; (iv) Nanosphere's ability to obtain regulatory approval of its products; (v) Nanosphere's ability to protect its intellectual property; (vi) competition and alternative technologies; and (vii) Nanosphere's ability to obtain additional financing to support its operations. Additional risks are discussed in the Company's current filings with the Securities and Exchange Commission. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts Investors: Roger Moody Chief Financial Officer Nanosphere, Inc. 847-400-9021 rmoody@nanosphere.us Michael Rice Founding Partner LifeSci Advisors 646-597-6979 mrice@lifesciadvisors.com Media: Lindsey Saxon Director of Communications Nanosphere, Inc. 847-400-9173 lsaxon@nanosphere.us Geoff Curtis Edelman 312-233-1253 geoff.curtis@edelman.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SAP Execution Can Steady Operations Beyond Spreadsheets

Updated Category News Views 114

Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...

Continue Reading
BBW Lawsuit Puts Guidance and Walmart Claims Under Lens

Updated Category News Views 65

A three-month slice of 2026 has landed Build-A-Bear in the sort of mess investors hate most: a securities complaint centered on whether management's upbeat messaging had already outrun the facts. The lawsuit targets purchases of BBW shares from May 28, 2026 through August 26, 2026, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 133

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 5

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines

Updated Category News Views 130

Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...

Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 52

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 11

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
Cybersecurity's AI Tailwind Meets a Brutal Market Test

Updated Category News Views 89

Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
RMT’s 12.4% Discount Still Demands a Much Harder Look

Updated Category News Views 119

A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...

Continue Reading

Top 5 Most Recently Viewed Articles

Saratoga Investment Corp. Set to Reveal Q1 Results with Insights

Updated Category News Views 159

Saratoga Investment Corp. Set to Announce Fiscal Q1 Results As the business world remains keenly focused on financial performances, Saratoga Investment Corp. (NYSE:SAR), a dedicated business development firm, is preparing to unveil its financial results for the quarter that concluded on May 31, 2025. This significant announcement is set to occur on a Tuesday, marking an...

Continue Reading
Great Circle Group Enhances Marine Services in Cape Cod Area

Updated Category News Views 241

Great Circle Group Expands Marine Services Great Circle Group has made a significant move by embracing a strategic alliance with three top marinas in Cape Cod and the Islands: MacDougalls', Falmouth Marine, and Vineyard Haven Marina. This collaboration positions Great Circle's Navtronics division as the key marine technology partner for these respected establishments,...

Continue Reading
Verizon Executive to Present at Citi 2024 Global TMT Conference

Updated Category News Views 198

Executive Insights at the Citi 2024 Global TMT Conference Verizon is excited to announce that Joe Russo, the Executive Vice President and President of Global Networks and Technology, will be representing the company at the Citi 2024 Global TMT Conference. This much-anticipated event is set for Thursday, September 5, at 9:10 a.m. ET. Attendees can expect engaging...

Continue Reading
ANI Pharmaceuticals’ Upcoming Participation in BioConnect Event

Updated Category News Views 247

ANI Pharmaceuticals to Present at BioConnect Conference ANI Pharmaceuticals, Inc. (Nasdaq: ANIP), located in Princeton, New Jersey, has exciting news for investors and stakeholders. The company is gearing up to participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference, an event that showcases innovative companies in the biopharmaceutical sector. Nikhil...

Continue Reading
Exciting Titanium Discoveries by NioBay Metals in Foothills

Updated Category News Views 99

NioBay Metals Reports Impressive Titanium Intercepts MONTRÉAL -- NioBay Metals Inc. (TSX-V: NBY) (OTCQB: NBYCF) is thrilled to share recent findings from its drilling operations at Zone 1 of the Foothills Property, highlighting significant titanium (TiO?) mineralization. This development brings the company one step closer to unlocking the potential of this resource-rich...

Continue Reading